Armando Giuliano, MD, has been a clinician-researcher for over 30 years. The main focus of his clinical research continues to be management of early breast cancer and quality of life of breast cancer patients. He served for five years as chairman of the Breast Organ Site Committee of the American College of Surgeons Oncology Group and was study chair for the sentinel node Z0010 and Z0011 studies which led to significant changes to the standard of care for patients with early breast cancer. He was previously a principal investigator for the NSABP and contributed to the lumpectomy study and to Alliance studies. He was a pioneer in sentinel node biopsy. This procedure has enabled early-stage breast cancer patients to avoid having more extensive surgery and reduces the incidence of complications such as lymphedema and shoulder problems. Giuliano also participates in translational research, merging what is learned in the clinic with knowledge gained in the laboratory. Under his direction, the scientists in the Breast Research Laboratory are actively studying triple negative breast cancer, BRCA-positive breast cancer, chemoresistance, and early metastases. Giuliano participates in the NCI's National Clinical Trials Network and is an active member of The Alliance for Clinical Trials in Oncology.